Going past the data for temozolomide (Q34093083)

31 July 2017

title

Going past the data for temozolomide (English)

1 reference

31 July 2017

0 references

2

Nathalie Letarte

1 reference

31 July 2017

J Lee Villano

1

1 reference

31 July 2017

Linda R Bressler

series ordinal

3

1 reference

31 July 2017

publication date

7 December 2011

1 reference

Cancer Chemotherapy and Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

69

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

1113-1115

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Secondary Ph+ acute lymphoblastic leukemia after temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1796-4

10.1007/S00280-011-1796-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1032275107

0 references

1 reference